This functionality is the basis for developing FGF21-based therapeutics and dual agonists, such as those combining FGF21 with glucagon-like peptide-1 (GLP-1), which are being explored for their efficacy in treating obesity and related metabolic disorders [28]. This evidence concerns the gene GCG and obesity disorder.